Tibsovo 250 mg
As listed in the register: Tibsovo 250 mg, comprimés pelliculés
250 mg ·
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Ivosidenibum
- Made by
- Servier (Suisse) SA
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Leucémie myéloïde aiguë (LMA) / Cholangiocarcinome
From the official label · 2026-09-30 · Swissmedic
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
Details
| Made by | Servier (Suisse) SA |
|---|---|
| Active substance | Ivosidenibum |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 250 mg |
| Classification | L01XM02 · Cancer treatments and immune-system medicines |
| Dispensing (as stated by the register) | Abgabekategorie A |
| Name in the register | Tibsovo 250 mg, comprimés pelliculés |
| Packs | 60 Tablette(n) |
| Zulassungsnummer | 69077 |
| Dosisstärke | 1 |
Source: Zugelassene Packungen Humanarzneimittel · 2026-09-30 · not reviewed by a clinician
Quelle: Swissmedic. The publisher’s terms do not grant reproduction, so text is shortened and linked. Publisher’s terms.